Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis
On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...